Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Annals of Behavioral Medicine
Erschienen in: Annals of Behavioral Medicine 1/2017

10.08.2016 | Original Article

Barriers to HIV Medication Adherence as a Function of Regimen Simplification

verfasst von: Yiyun Chen, MA, Kun Chen, PhD, Seth C. Kalichman, PhD

Erschienen in: Annals of Behavioral Medicine | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Barriers to HIV medication adherence may differ by levels of dosing schedules.

Purpose

The current study examined adherence barriers associated with medication regimen complexity and simplification.

Methods

A total of 755 people living with HIV currently taking anti-retroviral therapy were recruited from community services in Atlanta, Georgia. Participants completed audio-computer-assisted self-interviews that assessed demographic and behavioral characteristics, provided their HIV viral load obtained from their health care provider, and completed unannounced phone-based pill counts to monitor medication adherence over 1 month.

Results

Participants taking a single-tablet regimen (STR) were more likely to be adherent than those taking multi-tablets in a single-dose regimen (single-dose MTR) and those taking multi-tablets in a multi-dose regimen (multi-dose MTR), with no difference between the latter two. Regarding barriers to adherence, individuals taking STR were least likely to report scheduling issues and confusion as reasons for missing doses, but they were equally likely to report multiple lifestyle and logistical barriers to adherence.

Conclusions

Adherence interventions may need tailoring to address barriers that are specific to dosing regimens.
Literatur
1.
Antiretroviral Therapy Cohort, C., Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008; 372(9635): 293–9.CrossRef
2.
Harrison, K.M., R. Song, and X. Zhang, Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States. J Acquir Immune Defic Syndr 2010; 53(1): 124–30.CrossRefPubMed
3.
4.
Bangsberg, D.R., et al., Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001; 15(9):1181–3.CrossRefPubMed
5.
Nachega, J.B., et al., Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med 2007;146(8): 564–73.CrossRefPubMed
6.
Liu, H., et al., Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors. J Acquir Immune Defic Syndr 2006;41(3): 315–22.CrossRefPubMed
7.
Parruti, G., et al., Long-term adherence to first-line highly active antiretroviral therapy in a hospital-based cohort: predictors and impact on virologic response and relapse. AIDS Patient Care STDs 2006; 20(1): 48–56.CrossRefPubMed
8.
Bangsberg, D.R., Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. J Infect Dis 2008; 197 Suppl 3: S272–8.CrossRefPubMed
9.
Nachega, J.B., et al., Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs. Patient Prefer Adherence. 2011; 5: 357–67.CrossRefPubMedPubMedCentral
10.
Gallant, J.E., et al., Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354(3): 251–60.CrossRefPubMed
11.
Cohen, C.J., et al., Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011; 378(9787): 229–37.CrossRefPubMed
12.
Sax, P.E., et al., Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012; 379(9835):2439–48.CrossRefPubMed
13.
14.
Nachega, J.B., et al., Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV infection: A Meta-Analysis of Randomized Controlled Trials. Clin Infect Dis 2014; 58(9):1297–307.CrossRefPubMedPubMedCentral
15.
Cooper, V., et al., Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz. AIDS Care 2011; 23(6): 705–13.CrossRefPubMed
16.
Bangsberg, D.R., et al., A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS 2010; 24(18): 2835–40.CrossRefPubMedPubMedCentral
17.
Hanna, D.B., et al., Increase in single-tablet regimen use and associated improvements in adherence-related outcomes in HIV-infected women. J Acquir Immune Defic Syndr 2014; 65(5): 587–96.CrossRefPubMedPubMedCentral
18.
Cohen, C.J., J.L. Meyers, and K.L. Davis, Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV. BMJ Open. 2013; 3(8).
19.
Rao, G.A., et al., Impact of Highly Active Antiretroviral Therapy Regimen on Adherence and Risk of Hospitalization in Veterans with HIV/AIDS. Interscience Conference on Antimicrobial Agents and Chemotherapy. Denver, Colorado, USA; 2013.
20.
DeJesus, E., et al., Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine. HIV Clin Trials 2008; 9(2): 103–14.CrossRefPubMed
21.
Airoldi, M., et al., One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence 2010; 4:115–25.PubMedPubMedCentral
22.
Dejesus, E., et al., Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. J Acquir Immune Defic Syndr 2009; 51(2):163–74.CrossRefPubMed
23.
Hodder, S.L., et al., Patient-reported outcomes in virologically suppressed, HIV-1-infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir. AIDS Patient Care STDs 2010; 24(2): 87–96.CrossRefPubMed
24.
Buscher, A., et al., Impact of antiretroviral dosing frequency and pill burden on adherence among newly diagnosed, antiretroviral-naive HIV patients. Int J STD AIDS 2012; 23(5):351–5.CrossRefPubMedPubMedCentral
25.
Engsig, F., et al., Virological Response in Patients, Who for Economic Reasons Were Changed from Atripla to a Multi-tablet cART Regimen 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA, USA; 2013.
26.
Tennant, S.J., et al., Adherence among rural HIV-infected patients in the deep south: a comparison between single-tablet and multi-tablet once-daily regimens. J Int Assoc Provid AIDS Care 2015; 14(1): 64–71.CrossRefPubMed
27.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2015.
28.
Hodgson, I., et al., A systematic review of individual and contextual factors affecting ART initiation, adherence, and retention for HIV-infected pregnant and postpartum women. PLoS One 2014; 9(11): e111421.CrossRefPubMedPubMedCentral
29.
Katz, I.T., et al., Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis. J Int AIDS Soc 2013;16(3 Suppl 2): 18640.PubMedPubMedCentral
30.
Hendershot, C.S., et al., Alcohol use and antiretroviral adherence: review and meta-analysis. J Acquir Immune Defic Syndr 2009; 52(2): 180–202.CrossRefPubMedPubMedCentral
31.
Gribble, J.N., et al., The impact of T-ACASI interviewing on reported drug use among men who have sex with men. Subst Use Misuse 2000; 35(6–8):869–90.CrossRefPubMed
32.
Morrison-Beedy, D., M.P. Carey, and X. Tu, Accuracy of audio computer-assisted self-interviewing (ACASI) and self-administered questionnaires for the assessment of sexual behavior. AIDS Behav 2006; 10(5): 541–52.CrossRefPubMedPubMedCentral
33.
Kalichman, S.C., D. Rompa, and M. Cage, Reliability and validity of self-reported CD4 lymphocyte count and viral load test results in people living with HIV/AIDS. Int J STD AIDS, 2000. 11(9): 579–85.CrossRefPubMed
34.
Radloff, L.S., The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas, 1977. 1(3): p. 385–401.CrossRef
35.
Bangsberg, D.R., et al., Comparing objective measures of adherence to HIV antiretroviral therapy: electronic medication monitors and unannounced pill counts. AIDS Behav, 2001. 5: p. 275–281.CrossRef
36.
Kalichman, S.C., et al., Monitoring Antiretroviral adherence by unannounced pill counts conducted by telephone: Reliability and criterion-related validity. HIV Clin Trials 2008. 9: p. 298–308.CrossRefPubMedPubMedCentral
37.
Kalichman, S.C., et al., Adherence to antiretroviral therapy assessed by unannounced pill counts conducted by telephone. J Gen Intern Med 2007. 22: p. 1003–1006.CrossRefPubMedPubMedCentral
38.
Bangsberg, D.R., et al., Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS, 2000. 14(4): 357–66.CrossRefPubMed
39.
Catz, S.L., et al., Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol, 2000. 19(2): 124–33.CrossRefPubMed
40.
Rao, J.N.K. and A.J. Scott, The analysis of categorical data from complex sample surveys: chi-squared tests for goodness-of-fit and independence in two-way tables. J Am Stat Assoc, 1981;76: 221–230.CrossRef
41.
Lewinsohn, P.M., et al., Center for Epidemiological Studies-Depression Scale (CES-D) as a screening instrument for depression among community-residing older adults. Psychol Aging, 1997. 12: p. 277–287.CrossRefPubMed
42.
43.
Kalichman, S.C., et al., HIV treatment adherence in women living with HIV/AIDS: research based on the information-motivation-behavioral skills model of health behavior. J Assoc Nurses AIDS Care, 2001. 12(4): p. 58–67.CrossRefPubMed
44.
Zeger, S.L. and K.Y. Liang, Longitudinal data analysis for discrete and continuous outcomes. Biometrics, 1986. 42(1): p. 121–30.CrossRefPubMed
45.
Gifford, A.L., et al., Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr, 2000. 23(5): p. 386–95.CrossRefPubMed
46.
Benjamini, Y. and Y. Hochberg, Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B Met, 1995. 57: p. 289–300.
47.
StataCorp, Stata statistical software: release 13. 2013, College Station: StataCorp LP.
48.
ICAAC/American Society for Microbiolog. Effects on compliance and risk of hospitalization in veterans with HIV/AIDS taking single tablet vs. multiple tablets. 2013, Press release.
49.
Antinori, A., et al., Adherence in HIV-positive patients treated with single-tablet regimens and multi-pill regimens: findings from the COMPACT study. J Intern AIDS Soc, 2012. 15(Suppl 4): p. 18098.
50.
Langebeek, N., et al., Predictors and correlates of adherence to combination antiretroviral therapy (ART) for chronic HIV infection: a meta-analysis. BMC Med, 2014. 12: p. 142.CrossRefPubMedPubMedCentral
51.
Senkomago, V., et al., Barriers to antiretroviral adherence in HIV-positive patients receiving free medication in Kayunga, Uganda AIDS Care, 2011. 23(10): p. 1246–53.CrossRefPubMed
52.
Weiser, S., et al., Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J Acquir Immune Defic Syndr, 2003. 34(3): p. 281–8.CrossRefPubMed
53.
Mahajan, A.P., et al., Stigma in the HIV/AIDS epidemic: a review of the literature and recommendations for the way forward. AIDS, 2008. 22 Suppl 2: p. S67–79.CrossRefPubMedPubMedCentral
54.
Van Tam, V., et al., "it is not that I forget, it’s just that I don’t want other people to know": barriers to and strategies for adherence to antiretroviral therapy among HIV patients in northern Vietnam. AIDS Care, 2011. 23(2): p. 139–45.CrossRefPubMed
55.
Tessema, B., et al., Magnitude and determinants of nonadherence and nonreadiness to highly active antiretroviral therapy among people living with HIV/AIDS in Northwest Ethiopia: a cross-sectional study. AIDS Res Ther, 2010. 7: p. 2.CrossRefPubMedPubMedCentral
56.
57.
Tsai, A.C., et al., Internalized stigma, social distance, and disclosure of HIV seropositivity in rural Uganda. Ann Behav Med, 2013. 46(3): p. 285–94.CrossRefPubMed
58.
Lowther, K., et al., Experience of persistent psychological symptoms and perceived stigma among people with HIV on antiretroviral therapy (ART): a systematic review. Int J Nurs Stud, 2014. 51(8): p. 1171–89.CrossRefPubMed
59.
60.
Turner, B.J., et al., Barriers to adherence and hypertension control in a racially diverse representative sample of elderly primary care patients. Pharmacoepidemiol Drug Saf, 2009. 18(8): p. 672–81.CrossRefPubMed
61.
Lucas, G.M., et al., Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS, 2002. 16(5): p. 767–74.CrossRefPubMed
62.
Burkhart, P.V. and E. Sabate, Adherence to long-term therapies: evidence for action. J Nurs Scholarsh, 2003. 35(3): p. 207.PubMed
Metadaten
Titel
Barriers to HIV Medication Adherence as a Function of Regimen Simplification
verfasst von
Yiyun Chen, MA
Kun Chen, PhD
Seth C. Kalichman, PhD
Publikationsdatum
10.08.2016
Verlag
Springer US
Erschienen in
Annals of Behavioral Medicine / Ausgabe 1/2017
Print ISSN: 0883-6612
Elektronische ISSN: 1532-4796
DOI
https://doi.org/10.1007/s12160-016-9827-3

Weitere Artikel der Ausgabe 1/2017

Annals of Behavioral Medicine 1/2017 Zur Ausgabe

Erratum

Erratum to: Perceived Weight Discrimination and 10-year Risk of Allostatic Load Among US Adults

Original Article

Using Integrative Data Analysis to Examine Changes in Alcohol Use and Changes in Sexual Risk Behavior Across Four Samples of STI Clinic Patients

Original Article

The Impact of Interventions that Integrate Accelerometers on Physical Activity and Weight Loss: A Systematic Review

Original Article

Predictors of Smoking Cessation and Relapse in Cancer Patients and Effect on Psychological Variables: an 18-Month Observational Study

Original Article

Sleep Habits and Susceptibility to Upper Respiratory Illness: the Moderating Role of Subjective Socioeconomic Status

Original Article

Stress and Coping Predicts Adjustment and Glycemic Control in Adolescents with Type 1 Diabetes

Neu in den Fachgebieten Neurologie und Psychiatrie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Bildnachweise